Our Early-Stage Compounds​

Exelixis has a diverse portfolio of small molecule and biologics programs moving forward, covering a broad range of targets and therapeutic modalities. We are committed to further enhancing our early-stage pipeline and expanding our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians.

Program Name
Mechanism
Phase
  • Discovery/
    Preclinical
  • IND
  • Phase 1a
  • Phase 1b
  • Phase 2/3
Zanzalintinib (XL092)
Next-generation TKI targeting MET/
VEGFR/AXL/MER
Next-generation TKI targeting MET/
VEGFR/AXL/MER
  • Phase 2/3
XB002
Next-generation TF-targeting ADC
Next-generation TF-targeting ADC
  • Phase 1a
XL102
Potent, selective, orally bioavailable CDK7 inhibitor
Potent, selective, orally bioavailable CDK7 inhibitor
  • Phase 1a
CBX-12 Cybrexa Therapeutics
Novel exatecan peptide-drug conjugate
Novel exatecan peptide-drug conjugate
  • Phase 1a
ADU-1805 Sairopa
Monoclonal antibody targeting SIRPα
Monoclonal antibody targeting SIRPα
  • IND
XB010
Next-generation 5T4 targeting ADC
Next-generation 5T4 targeting ADC
  • Discovery/
    Preclinical
XB014
Bispecific antibody targeting PD-L1 + CD47
Bispecific antibody targeting PD-L1 + CD47
  • Discovery/
    Preclinical
XB628
Bispecific antibody targeting PD-L1 + NKG2A
Bispecific antibody targeting PD-L1 + NKG2A
  • Discovery/
    Preclinical
Invenra Collaboration Program
Non-disclosed
Non-disclosed
  • Discovery/
    Preclinical
Aurigene Collaboration Programs
CDK12 and MALT1 inhibitors
CDK12 and MALT1 inhibitors
  • Discovery/
    Preclinical
StemSynergy Collaboration Programs
CK1α activators and selective Notch inhibitors
CK1α activators and selective Notch inhibitors
  • Discovery/
    Preclinical
STORM Therapeutics Collaboration Program
ADAR1
ADAR1
  • Discovery/
    Preclinical
Exelixis Discovery Programs
PKMYT1 inhibitors
PKMYT1 inhibitors
  • Discovery/
    Preclinical
Biotherapeutics Program Invenra, NBE Therapeutics, Catalent, GamaMabs, WuXi, Adagene, BioInvent and Ryvu Theraputics Collaborations
AMHR2, ROR1/2, TF, DLL3
AMHR2, ROR1/2, TF, DLL3
  • Discovery/
    Preclinical

Additional undisclosed programs ongoing with Aurigene, Invenra, STORM Therapeutics and through internal Exelixis Discovery

  • ADAR1 = adenosine deaminase 1
  • ADC = antibody-drug conjugate
  • AMHR2 = anti-mullerian hormone receptor 2
  • CDK7 = cyclin-dependent kinase 7
  • CDK12 = cyclin-dependent kinase 12
  • CK1α = casein kinase 1 alpha
  • DLL3 = delta-like ligand 3
  • IND = Investigational New Drug application
  • MALT1 = mucosa associated lymphoid tissue lymphoma translocation gene 1
  • NKG2A = natural killer cell receptor group 2A
  • PKMYT1 = protein kinase, membrane associated tyrosine/threonine 1
  • ROR1/2 = receptor tyrosine kinase like orphan receptor 1/2
  • SIRPα = signal regulatory protein alpha
  • TF = tissue factor
  • TKI = tyrosine kinase inhibitor

Cabozantinib Pipeline

Explore the diverse development program for our flagship molecule

Learn More